上海药明巨诺生物科技有限公司 JW Therapeutics
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma 2024-08-27 17:00
Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress 2024-05-30 18:10
JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma 2024-01-04 21:40
JW Therapeutics Announces Exclusive Collaboration with 2seventy bio for Autoimmune Disease CAR-T Therapy 2024-01-02 20:15
JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus 2023-04-10 19:30
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients 2023-03-30 08:00
JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma 2023-03-08 17:30
JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma 2023-02-28 17:30
JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting 2022-12-12 18:00
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients 2022-11-09 17:00
JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies 2022-10-27 07:53
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma 2022-10-10 20:00
JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma 2022-07-04 19:30
JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting 2022-06-05 18:30
JW Therapeutics to Present Latest Data of Carteyva® at 2022 ASCO Annual Meeting 2022-05-09 09:00
JW Therapeutics to Present Latest Data of Carteyva® at 2022 ASCO Annual Meeting 2022-05-09 09:00
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 200 Chinese Patients 2022-04-25 15:08
JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva® in Pediatric and Young Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia 2022-04-20 18:30
JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China 2022-04-03 18:05
JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma 2022-03-31 12:20
1 2